Big Pharma Subdued In Its Response To Trump's Travel EO
Executive Summary
Big pharma has been muted in its response to President Trump's executive order imposing severe travel restrictions on nationals from seven Muslim-majority countries for 90 days. Small biotech, however, has no reservations about speaking out against the so-called 'immigration ban'.
You may also be interested in...
US Visa Concerns Led ICH To Choose Canadian Meeting Site
The US, one of ICH’s original three member authorities, was spurned in favor of Canada for the pharmaceutical regulatory harmonization initiative’s next meeting in the region because of some participants’ difficulties obtaining US visas.
Immigration Ban: BioPharma Response Varies From Silence To Dissent
While PhRMA, BIO and Pfizer had no response to President Trump’s travel order, Allergan and some smaller firms voiced their objections; PhRMA to meet with Trump on Tuesday.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.